104 related articles for article (PubMed ID: 10561375)
21. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
22. Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.
Campanelli R; Fois G; Catarsi P; Poletto V; Villani L; Erba BG; Maddaluno L; Jemos B; Salmoiraghi S; Guglielmelli P; Abbonante V; Di Buduo CA; Balduini A; Iurlo A; Barosi G; Rosti V; Massa M;
PLoS One; 2016; 11(6):e0156990. PubMed ID: 27281335
[TBL] [Abstract][Full Text] [Related]
23. Myelofibrosis and acquired hemophilia A: a case report.
Wrobel M; Comio E; Gay V; Baroudi N; Meyer P; Chuniaud-Louche C; Hacini M; Pica GM
J Med Case Rep; 2016 May; 10(1):115. PubMed ID: 27154067
[TBL] [Abstract][Full Text] [Related]
24. Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.
Singh NR
Transl Pediatr; 2015 Apr; 4(2):107-15. PubMed ID: 26835366
[TBL] [Abstract][Full Text] [Related]
25. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
26. Myeloproliferative Neoplasms in Children.
Hofmann I
J Hematop; 2015 Sep; 8(3):143-157. PubMed ID: 26609329
[TBL] [Abstract][Full Text] [Related]
27. Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis.
Lisette del C; Enrico B; Eleonora A; Riccardo G; Manlio M; Omar R
Case Rep Hematol; 2013; 2013():520712. PubMed ID: 24307957
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
29. WHO classification of myeloproliferative neoplasms (MPN): A critical update.
Kvasnicka HM
Curr Hematol Malig Rep; 2013 Dec; 8(4):333-41. PubMed ID: 24146204
[TBL] [Abstract][Full Text] [Related]
30. How I treat splenomegaly in myelofibrosis.
Cervantes F
Blood Cancer J; 2011 Oct; 1(10):e37. PubMed ID: 22829071
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Ostojic A; Vrhovac R; Verstovsek S
Ther Clin Risk Manag; 2012; 8():95-103. PubMed ID: 22399854
[TBL] [Abstract][Full Text] [Related]
32. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.
Stein BL; Rademaker A; Spivak JL; Moliterno AR
Thrombosis; 2011; 2011():874146. PubMed ID: 22084670
[TBL] [Abstract][Full Text] [Related]
33. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
[TBL] [Abstract][Full Text] [Related]
34. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
[TBL] [Abstract][Full Text] [Related]
35. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
36. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Thiele J; Kvasnicka HM
Curr Hematol Malig Rep; 2009 Jan; 4(1):33-40. PubMed ID: 20425436
[TBL] [Abstract][Full Text] [Related]
37. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.
Stein BL; Williams DM; Wang NY; Rogers O; Isaacs MA; Pemmaraju N; Spivak JL; Moliterno AR
Haematologica; 2010 Jul; 95(7):1090-7. PubMed ID: 20133898
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
[TBL] [Abstract][Full Text] [Related]
39. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.
Migliaccio AR; Martelli F; Verrucci M; Migliaccio G; Vannucchi AM; Ni H; Xu M; Jiang Y; Nakamoto B; Papayannopoulou T; Hoffman R
Exp Hematol; 2008 Feb; 36(2):158-71. PubMed ID: 18206727
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
